ANXA1 and focal segmental glomerulosclerosis: In the FSGS group, an increase in the level of both antibodies to annexin 1 and synaptopodin was observed in 20 (52.6%) out of 38 patients, while an increased level of one of the two antibodies was noted in 10 (26.3%) patients, and no increase in antibodies was observed in 8 (21.1%) patients.